Literature DB >> 18459074

A prospective pilot trial of ablation of Barrett's esophagus with low-grade dysplasia using stepwise circumferential and focal ablation (HALO system).

V K Sharma1, H Jae Kim, A Das, P Dean, G DePetris, D E Fleischer.   

Abstract

BACKGROUND AND STUDY AIMS: Yearly surveillance endoscopy is carried out for Barrett's esophagus with low-grade dysplasia (LGD) so that progression to high-grade dysplasia and adenocarcinoma can be detected at the earliest stage. The aim of the study was to assess the long-term safety and effectiveness of circumferential ablation followed by focal ablation (HALO system) for eliminating Barrett's esophagus and LGD. PATIENTS AND METHODS: Patients with 2 - 6 cm of Barrett's esophagus with histology demonstrating LGD on their last two sequential endoscopies over the previous 2 years and confirmed by two pathologists were enrolled in this prospective, single-center trial. Circumferential ablation was carried out at baseline and at 4 months (if residual Barrett's esophagus present). Endoscopy with 4-quadrant biopsies every 1 cm was performed at 1, 3, 6, 12, and 24 months. After 1 year, focal ablation was applied to any visible Barrett's esophagus or irregularity of the squamocolumnar junction. Patients received lansoprazole 30 mg bid. Complete responses for dysplasia (CR-dysplasia) and intestinal metaplasia (CR-IM) at 2-year follow-up, with complete response defined as "all biopsies negative for dysplasia or intestinal metaplasia" were the main outcomes.
RESULTS: Ten patients (nine men, mean age 66.9 years, range 48 - 79) with confirmed LGD (median 4.4 cm, range 3 - 6) underwent circumferential ablation with focal ablation after 1 year as necessary. At 2 years, CR-dysplasia was 100 % and CR-IM was 90 %. There were no strictures or buried intestinal metaplasia at follow-up.
CONCLUSION: A stepwise regimen of circumferential ablation followed by focal ablation appears to eradicate intestinal metaplasia (90 % CR-IM) and dysplasia (100 % CR-dysplasia) at 2-year follow-up in this trial, without stricture formation or buried intestinal metaplasia.

Entities:  

Mesh:

Year:  2008        PMID: 18459074     DOI: 10.1055/s-2007-995587

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  22 in total

1.  Radiofrequency ablation for dysplasia in Barrett's esophagus restores β-catenin activation within esophageal progenitor cells.

Authors:  K Krishnan; S Komanduri; J Cluley; R Dirisina; P Sinh; Jeff Z Ko; L Li; R B Katzman; T A Barrett
Journal:  Dig Dis Sci       Date:  2011-09-24       Impact factor: 3.199

2.  The cost effectiveness of radiofrequency ablation for Barrett's esophagus.

Authors:  Chin Hur; Sung Eun Choi; Joel H Rubenstein; Chung Yin Kong; Norman S Nishioka; Dawn T Provenzale; John M Inadomi
Journal:  Gastroenterology       Date:  2012-05-21       Impact factor: 22.682

Review 3.  Guidelines for surgical treatment of gastroesophageal reflux disease.

Authors:  Dimitrios Stefanidis; William W Hope; Geoffrey P Kohn; Patrick R Reardon; William S Richardson; Robert D Fanelli
Journal:  Surg Endosc       Date:  2010-08-20       Impact factor: 4.584

4.  Endoscopic resection techniques and ablative therapies for Barrett's neoplasia.

Authors:  Jacobo Ortiz-Fernández-Sordo; Adolfo Parra-Blanco; Alejandro García-Varona; María Rodríguez-Peláez; Erika Madrigal-Hoyos; Irving Waxman; Luis Rodrigo
Journal:  World J Gastrointest Endosc       Date:  2011-09-16

5.  Barrett's esophagus: endoscopic treatments II.

Authors:  Bruce D Greenwald; Charles J Lightdale; Julian A Abrams; John D Horwhat; Ram Chuttani; Srinadh Komanduri; Melissa P Upton; Henry D Appelman; Helen M Shields; Nicholas J Shaheen; Stephen J Sontag
Journal:  Ann N Y Acad Sci       Date:  2011-09       Impact factor: 5.691

6.  Durability of radiofrequency ablation in Barrett's esophagus with dysplasia.

Authors:  Nicholas J Shaheen; Bergein F Overholt; Richard E Sampliner; Herbert C Wolfsen; Kenneth K Wang; David E Fleischer; Virender K Sharma; Glenn M Eisen; M Brian Fennerty; John G Hunter; Mary P Bronner; John R Goldblum; Ana E Bennett; Hiroshi Mashimo; Richard I Rothstein; Stuart R Gordon; Steven A Edmundowicz; Ryan D Madanick; Anne F Peery; V Raman Muthusamy; Kenneth J Chang; Michael B Kimmey; Stuart J Spechler; Ali A Siddiqui; Rhonda F Souza; Anthony Infantolino; John A Dumot; Gary W Falk; Joseph A Galanko; Blair A Jobe; Robert H Hawes; Brenda J Hoffman; Prateek Sharma; Amitabh Chak; Charles J Lightdale
Journal:  Gastroenterology       Date:  2011-05-06       Impact factor: 22.682

Review 7.  Buried metaplasia after endoscopic ablation of Barrett's esophagus: a systematic review.

Authors:  Nathan A Gray; Robert D Odze; Stuart Jon Spechler
Journal:  Am J Gastroenterol       Date:  2011-08-09       Impact factor: 10.864

Review 8.  Ablative therapies for Barrett's esophagus.

Authors:  Katherine S Garman; Nicholas J Shaheen
Journal:  Curr Gastroenterol Rep       Date:  2011-06

Review 9.  Endoscopic Radiofrequency Ablation of the Pancreas.

Authors:  Tarun Rustagi; Ankit Chhoda
Journal:  Dig Dis Sci       Date:  2017-02-03       Impact factor: 3.199

Review 10.  Endoscopic ablation of Barrett's esophagus using the Halo system.

Authors:  David E Fleischer; Virender K Sharma
Journal:  Dig Dis       Date:  2009-01-30       Impact factor: 2.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.